Skip to main content

Table 1 Basic characteristics of included studies

From: Diffusion-weighted imaging in monitoring the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis

Study Year Study design No. of cases Age (mean range) Disease stages Histologic subtype Magnet strenth (T) Duration of the patients (years, month) Blind Timing of evaluation
Agarwal 2017 NR 38 44.2(19–65) LABC, stage II/III IDC/DCIS 1.5 T NR   Pre-NAC and after 1.3 cycles
Atuegwu 2013 NR 28 44.9 (28–67) Stage II/III NR 3.0 T NR   Pre-NAC and after 1 cycle, and post-NAC
Belli 2011 Pro 51 48.4 (26–66) NR IDC/ILC 1.5 T 2007.01–2009.01 Blind Pre-NAC and post-NAC within 4 weeks
Bufi 2014 Retro 225 47 (26–67) Stage II/III IDC/ILC 1.5 T 2007–2012 Blind Pre-NAC and post-NAC within 4 weeks
Bufi 2015 Retro 225 47 (26–67) LABC, stage II/III/IV IDC/ILC 1.5 T 2007–2012 Blind Pre-NAC and post-NAC within 4 weeks
Che 2016 NR 36 50.9 (27–75) LABC IDC/ILC 3.0 T 2014.03–2015.05 Blind Pre-NAC and after 2 cycles
Fangberget 2010 Pro 31 50.7 (37–72) Stage II/III/IV IDC/ILC 1.5 T 2007.04–2008.10 Blind Pre-NAC and after 4 cycles, and post-NAC
Fujimoto 2013 NR 56 50.9(27–70) Stage II/III IDC 1.5 T 2006.02–2009.12 Blind Pre-NAC and post-NAC within 3 weeks
Li 2011 Pro 32 46 (25–63) LABC NR 1.5 T 2007.07–2010.07   Pre-NAC and after 1 cycle
Li 2015 Pro 42 46.8 (28–67) Stage II/III NR 3.0 T NR   Pre-NAC and after 1 cycle, post-NAC
Luo 2014 Retro 71 46.1 (29–72) NR IDC 3.0 T 2010.03–2012.12 Blind Pre-NAC, after 2 cycles and post-NAC
Mani 2013 NR 28 45 (28–67) Stage II/III NR NR NR   Pre-NAC, after 1 cycle and post-NAC
Study Year Study design No. of cases Age (mean range) Disease stages Histologic subtype Magnet strenth(T) Duration of the patients (year, months) Blind Timing of evaluation
Park 2010 Retro 53 43.7 (24–65) Stage II/III IDC/ILC 1.5 T 2007.03–2008.05 Blind Pre-NAC and after 3 cycles
Park 2011 Retro 34 44 (27–60) LABC IDC/ILC 1.5 T 2007.04–2008.05 Blind Pre-NAC and after 3–6 cycles
Richard 2013 Retro 118 53.2 (23–83) LABC, stage II/III/IV IDC/ILC 1.5 T 2008.07–2011.05 Blind Pre-NAC and post-NAC less than 2 weeks
Sharma 2009 Retro 56 48.5 (25–75) LABC IDC 1.5 T 2003.12–2006.12   Pre-NAC and after 1, 2, 3 cycles
Shin 2012 Retro 90 46 (24–68) Stage I/II/III IDC/ILC 1.5 T 2009.01–2011.05   Pre-NAC and post-NAC
Weis 2015 Retro 33 46 (28–67) Stage II/III NR 3.0 T NR   Pre-NAC, after 1 cycle and post-NAC
Woodhams 2010 NR 69 NR NR IDC/ILC 1.5 T 2005.01–2008.10 Blind Pre-NAC, after 4 cycles the post-NAC
Xu 2017 NR 174 45.7 (28–64) LABC, stage II/III IDC/ILC 3.0 T 2011.09–2014.12 Blind Pre-NAC, after 1 cycle and post-NAC
  1. LABC locally advanced breast cancer; IDL invasive ductal carcinoma; ILC invasive lobular carcinoma; Pro prospective; Retro retrospective; NR not reported